About this trial
Currently the prevalent approach to perioperative management of patients is ERAS (Enhanced Recovery After Surgery) concept. This approach includes numerous aspects, among which the perioperative use of multimodal analgesia takes one of the leading places. Within the ERAS guidelines all sorts of minimization of opioid analgesics use in schemes of postoperative analgesia are appreciated. Thus, new pharmacological approaches are being actively developed currently in order to achieve adequate analgesia and to minimize the use of this group of drugs.
One of the most perspective trends within the multimodal analgesia concept is continuous infusion of non-steroidal anti-inflammatory drugs (NSAID). Up to date there are papers that both confirm the effectiveness of this method for maintaining adequate postoperative analgesia and show its limitations and deny the advantages of the continuous use of NSAID.
Up to this time the main attention of the medical community was paid for such drugs as paracetamol and ketoprofen. Nevertheless, one of the most common and safe NSAID is ibuprofen. In spite of this, there are no studies that explore the effectiveness of the continuous infusion of this drug. Thus, the lack of even low-quality evidence led to setting up a study of effectiveness and safety of continuous infusion of ibuprofen in comparison to its bolus injection.
Eligibility criteria
Qualifiers
Age > 18 years old
Elective laparoscopic surgery
General anesthesia
Signed informed consent from the patient to participate in the study
Disqualifiers
History of ibuprofen allergy
Active erosive or ulcerative lesions of the gastrointestinal tract
Chronic use of opioid analgesics or NSAIDs prior to enrollment
Chronic kidney disease ≥ 3b stage according to the KDIGO classification
Trial design
Treatments tested in this trial
- Ibuprofen continuous infusion
- Ibuprofen bolus injection
Treatment groups
Locations
1Map coordinates are unavailable for these locations. Locations are shown below instead.